DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) CEO Saiid Zarrabian bought 60,900 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average price of $0.82 per share, for a total transaction of $49,938.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
DelMar Pharmaceuticals, Inc. (DMPI) opened at $0.92 on Monday. DelMar Pharmaceuticals, Inc. has a one year low of $0.78 and a one year high of $5.39.
DelMar Pharmaceuticals (NASDAQ:DMPI) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). equities analysts forecast that DelMar Pharmaceuticals, Inc. will post -0.6 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Susquehanna International Group LLP bought a new position in DelMar Pharmaceuticals in the third quarter valued at approximately $306,000. Sabby Management LLC bought a new position in DelMar Pharmaceuticals in the second quarter valued at approximately $1,484,000. Finally, Franklin Resources Inc. bought a new position in DelMar Pharmaceuticals in the second quarter valued at approximately $2,477,000. 16.91% of the stock is currently owned by hedge funds and other institutional investors.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.